Autolus Therapeutics' Leukemia Trial Meets Primary Goal Of Remission Rate, Shares Fall After $150M Capital Raise

Vandana Singh
·1 min read

  • Autolus Therapeutics plc's (NASDAQ: AUTL) Phase 2 pivotal FELIX trial of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult Acute Lymphoblastic Leukemia (ALL) has met its primary endpoint of Overall Remission Rate (ORR).

  • The data comes from a pre-planned interim analysis of 50 patients.

  • The ORR for obe-cel was 70%. Obe-cel showed comparable expansion and initial persistence (median follow-up 6.4 months) to the data observed in the prior ALLCAR19 study.

  • The safety analysis was based on 92 patients treated with obe-cel and evaluable for safety.

  • The company observed that 3% of patients experienced Grade 3 or higher CRS, 8% experienced Grade 3 or higher ICANS, and 23% experienced any grade ICANS.

  • Autolus plans to present the results from the FELIX trial, with a longer follow-up planned to be reported at the end of 2023.

  • Blackstone Life Sciences has committed two pre-agreed milestone payments of $70 million to Autolus due to the interim analysis of the FELIX Phase 2 trial.

  • Concurrently, Autolus has priced 75 million ADSs representing 75 million shares at $2.00 per ADS, for total gross proceeds of $150 million.

  • Underwriters have the option to purchase up to an additional 11.25 million ADSs.

  • Price Action: AUTL shares closed 29.10% lower at $2.12 during premarket trading on the last check Friday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Recommended Stories